ABSTRACT
Although the pharmaceutical industry is a leader in scientific and technical innovation, it has been slow to adopt business enhancement practices successfully implemented years earlier in the automotive, electronic, and aerospace industries. In response to business pressures or crises, other industries have gone back to the basics and have progressed in line with a fundamental business analysis where core competences-those skills that provide differentiation and therefore competitive advantage-are identified and enhanced through internal development and external access. Those activities identified as noncore activities are contracted out, leaving personnel and financial resources focused on the highest value-added business components.
